Report : South and Central America Low Molecular Weight Heparin Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Product Type (Enoxaparin, Dalteparin, Tinzaparin, Fraxiparine, Nadroparin, and Others), Packaging (Multi-Vials and Prefilled Syringes), Application [Deep Vein Thrombosis, Acute Coronary Syndrome (ACS), Pulmonary Embolism, and Others], and End User (Hospitals, Clinics, Ambulatory Surgical Centers, and Others)
Multi-Vials Segment to Dominate South and Central America Low Molecular Weight Heparin Market during 2019–2028
According to a new market research study on “South and Central America Low Molecular Weight Heparin Market to 2028 – COVID-19 Impact and Regional Analysis and Forecast by Product Type, Packaging, Application, and End User,” is expected to reach US$ 303.39 million by 2028 from US$ 202.69 million in 2021. The market is estimated to grow at a CAGR of 5.9% from 2021 to 2028. Advantages of low molecular weight heparin over unfractionated heparin is the major factor driving the growth of the South and Central America low molecular weight heparin market. However, adverse issues of low molecular weight heparin during treatment may hinder the growth of South and Central America low molecular weight heparin market. The report provides trends prevailing in the South and Central America low molecular weight heparin market along with the drivers and restraints pertaining to the market growth.
Countries in South and Central America are famous for medical tourism, but they have seen adverse effects of the COVID-19 pandemic in the past two years. After the onset of the second wave of the COVID-19 outbreak, there were 5,395,044 new cases in Argentina. Thus, the region was on the verge of imposing the second lockdown in 2021. In 2020, the market stakeholders lost their businesses due to the shutdown of their businesses for indefinite periods. SARS-2-CoV can contribute to VTE or arterial disease due to increased inflammatory response, hypoxia, immobilization, and DIC. The risk of developing VTE is higher in critically ill COVID-19 patients. In addition to hemostatic changes, immobility, systemic inflammatory status, mechanical ventilation, and central catheters increase the risk of thromboembolism, while diet-related and hepatic changes alter the production of coagulation factors. Identified risk factors for VTE include hospitalization in the intensive care unit, and higher white blood cell count, neutrophil/lymphocyte ratio, and D-dimer value. The COVID-19 pandemic can affect the prevention and treatment of thrombotic or thromboembolic diseases in different ways. The protocols for thromboprophylaxis, anticoagulation, and additional considerations for the management of coagulation disorders and the bleeding should be implemented in each facility by the most current recommendations in the region.
The South and Central America low molecular weight heparin market is segmented into product type, packaging, application, end user and country. The South and Central America low molecular weight heparin market, based on product type, has been segmented into enoxaparin, dalteparin, tinzaparin, fraxiparine, nadroparin, and others. The enoxaparin segment held the largest share of the market in 2021. The South and Central America low molecular weight heparin market based on packaging is segmented into multi-vials and prefilled syringes. In 2021, the multi-vials segment held the largest share of the market. The South and Central America low molecular weight heparin market, based on application, has been segmented into deep vein thrombosis, acute coronary syndrome (ACS), pulmonary embolism, and others. The deep vein thrombosis segment held the largest share of the market in 2021. The South and Central America low molecular weight heparin market, based on end user, has been segmented into hospitals, clinics, ambulatory surgical centers, and others. The hospitals segment held the largest share of the market in 2021. Similarly, based on country, the market is bifurcated into Brazil, Argentina, and rest of South and Central America. Brazil held the largest share of the South and Central America low molecular weight heparin market in 2021.
Abbott, Aspen Holdings, B. Braun Medical Inc., Dr. Reddy's Laboratories, LEO Pharma A/S, Novartis, Pfizer Inc., Sanofi, and TEVA PHARMACEUTICAL INDUSTRIES LTD are among the leading companies in the South and Central America Low Molecular Weight Heparin Market. The companies are focused on adopting organic growth strategies such as product launches and expansions to sustain their position in the dynamic market. For instance, in 2018, Dr Reddy's Laboratories Ltd has launched the antiepileptic drug, Levetiracetam in Sodium Chloride Injection, in multiple strengths.
Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@businessmarketinsights.com